4536 Stock Overview
Engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Santen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,549.00 |
| 52 Week High | JP¥1,878.50 |
| 52 Week Low | JP¥1,372.00 |
| Beta | 0.21 |
| 1 Month Change | -6.86% |
| 3 Month Change | -11.79% |
| 1 Year Change | 12.53% |
| 3 Year Change | 9.70% |
| 5 Year Change | -26.76% |
| Change since IPO | 400.76% |
Recent News & Updates
Santen Pharmaceutical (TSE:4536) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Nov 18
Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next
Nov 11Recent updates
Santen Pharmaceutical (TSE:4536) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Nov 18Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next
Nov 11Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Share Price Could Signal Some Risk
Oct 14Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)
Aug 31Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 08Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares
Jun 25Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
May 11Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?
May 08Shareholder Returns
| 4536 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -7.7% | -1.2% | -0.9% |
| 1Y | 12.5% | 9.8% | 13.7% |
Return vs Industry: 4536 exceeded the JP Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: 4536 underperformed the JP Market which returned 13.7% over the past year.
Price Volatility
| 4536 volatility | |
|---|---|
| 4536 Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.4% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4536 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4536's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1890 | 3,744 | Takeshi Ito | www.santen.com |
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension.
Santen Pharmaceutical Co., Ltd. Fundamentals Summary
| 4536 fundamental statistics | |
|---|---|
| Market cap | JP¥530.71b |
| Earnings (TTM) | JP¥26.12b |
| Revenue (TTM) | JP¥302.56b |
20.3x
P/E Ratio1.8x
P/S RatioIs 4536 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4536 income statement (TTM) | |
|---|---|
| Revenue | JP¥302.56b |
| Cost of Revenue | JP¥127.31b |
| Gross Profit | JP¥175.26b |
| Other Expenses | JP¥149.13b |
| Earnings | JP¥26.12b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 76.25 |
| Gross Margin | 57.92% |
| Net Profit Margin | 8.63% |
| Debt/Equity Ratio | 0% |
How did 4536 perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield68%
Payout RatioDoes 4536 pay a reliable dividends?
See 4536 dividend history and benchmarks| Santen Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2025 |
| Dividend Pay Date | Jun 26 2025 |
| Days until Ex dividend | 98 days |
| Days until Dividend pay date | 188 days |
Does 4536 pay a reliable dividends?
See 4536 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 17:51 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Santen Pharmaceutical Co., Ltd. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Philip Hall | BNP Paribas Securities (Asia) |
| Koichi Mamegano | BofA Global Research |